

KFIN/CERT13(3)/DEC/2023 Date: January 6, 2024

Mr. Ajay Nadkarni

M/s. GlaxoSmithKline Pharmaceuticals Limited

Dr. Annie Besant Road Worli, Mumbai-400025.

Sub: Investor Grievance Certificate for the quarter ended December 31, 2023.

Dear Sir,

With reference to the above, we are pleased to furnish below the status of the Investor complaints under SEBI (Listing Obligations & Disclosure requirements), Regulations, 2015 for the quarter ended December 31, 2023.

Description of	Opening	Received during the	Attended/Resolved	Pending as on
Complaint	Balance as on	Period 01.10.2023	during the Period	31.12.2023
	01.10.2023	to 31.12.2023	01.10.2023 to	
			31.12.2023	
Non-receipt of	NIL	10	10	NIL
Dividend				
Non-receipt of	NIL	NIL	NIL	NIL
Annual reports				
Non receipt of	NIL	03	03	NIL
shares				
SEBI	NIL	NIL	NIL	NIL
Stock Exchange	01	09	10	NIL
Total	01	22	23	NIL

This is for your information and record.

Thanking you,

Yours faithfully For KFin Technologies Limited

Rajitha Cholleti Dy. Vice President

KFin Technologies Limited 🔘

(Formerly known as KFin Technologies Private Limited)

Registered & Corporate Office:

Selenium Building, Tower-B, Plot No- 31 & 32, Financial District, Nanakramguda, Serilingampally, Hyderabad, Rangareddi, Telangana, India, 500032.

CIN: L72400TG2017PLC117649

